Exenatide and rimonabant: New treatments that may be useful in the management of diabetes and obesity
- First Online:
- 50 Downloads
Diabetes mellitus and obesity have become increasingly prevalent problems worldwide. Unfortunately, with traditionally prescribed glucose-lowering medications most individuals with diagnosed diabetes do not achieve and maintain adequate glycemic control over time; it may be even more challenging to lower blood glucose to an appropriate level without inducing a significant associated weight gain. Exenatide and rimonabant are recently developed agents that have demonstrated benefit in both glucose lowering and reduction of body weight. These medications may well prove to be attractive alternatives or additions to our more established diabetes therapies; however, these drugs have a side-effect profile that may limit their applicability to certain populations.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 23.Buse JB, Klonoff DC, Nielsen LL, et al.: Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007, 29:139–153.PubMedCrossRefGoogle Scholar
- 28.Amylin Pharmaceuticals: Exenatide prescribing information. http://www.BYETTA.com/index.jsp. Accessed May 14, 2007.
- 30.Kim D, MacConnell L, Zhuang D, et al.: Safety and efficacy of a once-weekly, long-acting release formulation of exenatide over 15 weeks in patients with type 2 diabetes (abstract 487-P). Diabetes 2006, 55:116.Google Scholar
- 41.Curioni C, Andre C: Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006, (4):CD006162.Google Scholar